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Introduction: Small cell lung cancer (SCLC) constitutes a
distinct component of symptomatic or advanced-stage lung
cancers in clinical practice and in lung cancer screening
trials. The purpose of this study was to describe the
outcome of SCLC in lung cancer screening trials and
compare the frequency of SCLC in our cohort with that in
the major lung cancer screening trials.
Methods: Subjects with a diagnosis of SCLC were selected
from two lung cancer screening trials by low-dose
computed tomography (LDCT), and their demographic
characteristics, clinical parameters, tumor stage at diag-
nosis, therapy, and survival times were recorded. Survival
curves were estimated using the Kaplan-Meier method.
Results: Ten cases of SCLC were reported in 45,141 person-
years (22 in 100,000 person-years), representing the 6% of
all lung cancer cases. Cumulative tobacco consumption was
82 pack-years compared with 39 and 46 pack-years for the
overall study population and subjects with non-SCLC,
respectively. Most of the neoplasms were in an advanced
stage (seven in stage IV and one each in stages IIIb, IIIa, and
Ia). Two subjects were treated with lobectomy for curative
purposes and died of diffuse metastasis within 2 years of
diagnosis. The median overall survival time in the LDCT
arms was 20.6 months, with no survivors remaining at 3
years.
Conclusions: Subjects in whom SCLC develops are a sub-
group of smokers with extremely high cumulative tobacco
consumption. Consequently, the frequency of SCLC in our
population was lower than in other screening populations,
with higher cumulative tobacco consumption. Screening forlung cancer by LDCT does not improve survival of SCLC,
with no survivors remaining at 3 years after diagnosis.
 2015 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
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Introduction
Small cell lung cancer (SCLC) accounts for approxi-
mately 13% of all lung cancers1 and its prevalence is
directly related to cigarette smoking.2 Only 30% of SCLC
is diagnosed as limited-stage SCLC (LS-SCLC), whereas
the majority of cases show extensive-stage SCLC (ES-
SCLC) related to either massive thoracic involvement or
systemic diffusion.3 The 5-year survival rate for SCLC in
Europe ranges from 2.2% to 3.7%, which is consistently
lower than the 10.8% to 14.0% survival rate for non–
small cell lung cancer (NSCLC).4 A trivial increase in
survival of LS-SCLC compared with ES-SCLC is seen.2,5,6
The frequency of SCLC has been described within
lung cancer screening trials using low-dose computedJournal of Thoracic Oncology Vol. 11 No. 2: 187-193
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screening programs, with an incidence of 26 cases in
100,000 person-years in Europe7 and 83 cases in
100,000 in the United States.8 Because of its aggressive
biology, SCLC constitutes a consistently large percentage
of the cases of symptomatic interval cancers or asymp-
tomatic diffuse disease that are discovered during yearly
LDCT screening.8 To date, there has been no report
about the outcome of SCLC with lung cancer screening.
The purpose of this study was twofold: to describe
the outcome of SCLC in lung cancer screening trials and
compare the frequency of SCLC between our cohort and
those of the major lung cancer screening trials.
Materials and Methods
For the purpose of this study, we retrospectively
reviewed data from two lung cancer screening trials
based in Milan. The details of these screening programs
were described elsewhere.10,11 In brief, in 2000 a 5-year
prospective pilot trial offering yearly LDCT to 1035 vol-
unteers who were currently or formerly heavy smokers,
had a smoking history of 20 ormore pack-years, andwere
at least 50 years old was launched.10 Five years later, the
Multicentric Italian Lung Detection (MILD) trial started
with prospective enrollment of 4099 volunteer heavy
smokers with the same characteristics as those of the
volunteers in the previous trial. Volunteers were
randomly assigned to a control arm or an early detection
arm; the subjects in the latter group were randomly
assigned to either annual or biennial LDCT.11 Further-
more, primary prevention was offered to all participants
through a smoking cessation program. For the present
analyses, the follow-up lasted until August 2015.
Subjects with a diagnosis of SCLC were selected and
their demographics and clinical parameters were
collected from the database. The results of the diagnostic
work-up of each subject were recorded, and stage of the
disease was assessed at the time of diagnosis. In
particular, stage of disease was assessed according to
both the tumor, node, and metastasis (TNM) staging
system12 and an SCLC-dedicated two-stage clinical sys-
tem (e.g., LS-SCLC and ES-SCLC),13 the latter being the
standard method for clinical management. Descriptions
of therapeutic management were retrieved from clinical
records, and follow-up was conducted through active
telephone contact and record linkage with national
administrative databases. Cause of death was collected
for all deceased subjects, and overall survival was
calculated as index of outcome.Statistical Analyses
Continuous variables were presented as median
values and ranges, and categorical variables werereported as numbers and percentages. Survival curves
were estimated using the Kaplan-Meier method. Statisti-
cal analyses were performed using STATA statistical
software (version 11; StataCorp, College Station, TX).
Results
A total of 5134 subjects were recruited and followed
up for a median time of 8.3 years, with 45,141 person-
year of clinical follow-up. Ten cases of SCLC were re-
ported, with an incidence of SCLC of 22 cases in 100,000
person-years. SCLC accounted for 10 of all 164 lung
cancer cases (6%) diagnosed in the screening. SCLC was
diagnosed in 3 of 1643 women and 7 of 3385 men; their
median age at diagnosis was 65 years (range 53 to 73
years) compared with 57 years for the overall popula-
tion (range 50 to 75 years). Their cumulative tobacco
consumption was 82 pack-years (range 30 to 113 pack-
years) as compared with 39 pack-years (range 20 to 216
pack-years) for the overall study population and 46
pack-years (range 21 to 162 pack-years) for the subjects
with NSCLC. Eight subjects were current smokers at the
time of SCLC diagnosis, and two subjects were ex-
smokers with a diagnosis of SCLC at 2 and 6 years
after they had quit smoking quitting, with cumulative
tobacco consumptions of 84 and 80 pack-years during
their 42 and 40 years of smoking history at their age of
diagnosis (63 and 66 years), respectively.
Eight cases of SCLC were reported in the LDCT arms
(three in a pilot study, two in the annual LDCT arm of
MILD, and three in the biennial LDCT arm of MILD
[Table 1]), and two were reported in a control group. Six
of the eight SCLC cases reported in the LDCT arms were
detected by LDCT before onset of symptoms (Fig. 1). In
addition, two SCLC from the LDCT armswere not detected
by scan, one of which was assigned to an annual arm and
the other to an biennial arm (Fig. 2). The two subjects
were referred for medical care for symptoms during the
sixth and ninth intervals between screening rounds.
Two subjects had previous malignancies, namely,
epidermoid NSCLC (diagnosed within the annual LDCT
arm of MILD) or cutaneous melanoma. Three subjects
had a family history of lung cancer. None of the 10
subjects with SCLC showed signs of paraneoplastic syn-
drome. Nine subjects underwent clinical staging by 18F-
ﬂuorodeoxyglucose–positron emission tomography
(18FDG-PET). The median standard uptake value for
SCLC was 10 (range 5.5 to 14.4).
According to the clinical TNM classiﬁcation, all but
one of the cases of SCLC were at an advanced stage at the
time of diagnosis, speciﬁcally, seven cases with stage IV
disease, one case with stage IIIb disease, one case with
stage IIIa disease, and 1 case with stage Ia disease. In
particular, four of the seven cases of stage IV SCLC were
either from the control group (two cases) or cases from
Table 1. Characteristics and Smoking History of Subjects
with SCLC in the LDCT Armsa
Parameter
Subjects with SCLC
in LDCT Arms
(n ¼ 8)
Ratio of females to males 3:5
Smoking history
Duration, y 40 (40–48)
Pack-years 85 (30–113)
Ratio of former to current
smokers
1:7
Previous lung cancer 1
Family history of lung cancer
Yes 3
No 5
Age at diagnosis, y 66 (60–73)
Screen detection
Yes 6
No 2
Screening round, y 6.5 (3–10)
Previous screen recall for CT
ﬁndings other than tumor
Yes 4
No 4
SUV at 18FDG-PET 10 (5.5–14.4)
Stage:
Limited 5
Extensive 3
aSubjects’ demographic characteristics, screen detection, diag-
nostic work-up, clinical staging, and survival are reported for SCLC
detected in the LDCT arms. Continuous variables are reported in
terms of median and range.
SCLC, small cell lung cancer; LDCT, low-dose computed tomogra-
phy; SUV, standard uptake value; 18FDG-PET, 18F-ﬂuorodeox-
yglucose–positron emission tomography.
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(two cases).
LS-SCLC accounted for 62.5% of cases (ﬁve of eight)
in LDCT arms, with 66.7% (four of six) among the
screen-detected neoplasms and 50% (one of two) among
those not detected by screening. In the control group,
100% of subjects had symptomatic ES-SCLC (e.g., they
were referred for medical investigation because of un-
resolving pneumonia or persistent dyspnea).
The rate of non-screen-detected SCLC was two of
eight (25%) in the whole series. In the sole MILD trial,
non-screen-detected cancer occurred more frequently
among cases of SCLC (two of ﬁve, 40%) than among
cases of NSCLC (19 of 84, 22.6%), with SCLC repre-
senting 9.5% of all non-screen-detected tumors and
8.6% of all interval cancer cases.
Only two subjects underwent surgical resection by
lobectomy: one subject with stage Ia disease underwent
lobectomy for curative purposes (tumor diameter 10
mm, none of 14 lymph nodes examined showed meta-
static involvement), but mediastinal lymph node relapseoccurred in that subject after 8 months. Therefore,
she was given chemotherapy and radiation therapy;
however, she died of disseminated metastases after 19
months. One subject with stage IIIa disease underwent
lobectomy by thoracotomy but died of systemic metas-
tases 18 months after initial diagnosis. The remaining
subjects were treated as follows: three subjects were
given chemotherapy only and four received combined
chemotherapy and radiation therapy. First-line chemo-
therapy with cisplatin and etoposide was the only phar-
macological treatment administered to ﬁve subjects,
whereas two were also treated with second-line chemo-
therapy based on a topoisomerase inhibitor. Radio-
therapy was focused on the mediastinum and brain in all
three subjects who received it for curative purposes, and
one subject underwent palliative radiation therapy to the
left humerus and thoracic spine for pain control.
Three subjects were still alive at the time of the ﬁnal
clinical follow-up (three subjects had stage IV disease
with survival times after diagnosis of 9, 22, and 33
months). The median overall survival time for the whole
series was 20.0 months (95% conﬁdence interval [CI]:
11.5 to not calculable months) (Fig. 3). The subjects from
LDCT arms had a median overall survival time of 20.6
months (95% CI: 13.6 to nc months), with a survival time
of 22.7 months for those with screen-detected SCLC (95%
CI: 15.4 to nc months), 9 months and 22 months for the
two with non-screen-detected SCLC (both were alive and
in stage IV at the time of this study), 26.9 months for
those with LS-SCLC (95% CI: 18.9 to nc months), and 14.8
months for those with ES-SCLC (95% CI: 6.6 to nc
months). The overall survival times of the two subjects
with SCLC in the control group were 7.6 and 21.6 months.
There were no survivors at the 3-year follow-up (Fig. 3).Discussion
A total of 10 cases of SCLC were diagnosed in 45,141
person-years (22 in 100,000 person-years), with SCLC
accounting for 6% of all tumors in the two screening
trials. In LDCT arms, two of eight SCLC cases (25%) were
non-screen-detected interval cancers. The tumors in
LDCT arms were LS-SCLC in 62.5% of cases and ES-SCLC
in 37.5%, whereas all the tumors in the control group
were ES-SCLC. The outcome of SCLC remained unsatis-
factory, with a median survival time of 26.9 months for
LS-SCLC and no survivors at 3-year follow-up despite the
one case of stage Ia SCLC that had been treated with
radical surgery.
Clinical reports show extremely short survival of
SCLC2 and minor improvement in therapy during the
past 25 years, with a median overall survival time of 15
to 20 months for LS-SCLC alone.14 In lung cancer
screening trials, SCLC is still being diagnosed in TNM
Figure 1. Screen-detected extensive-stage single cell lung cancer (SCLC) in a participant undergoing biennial low-dose
computed tomography scan. SCLC is an extremely aggressive histotype of lung cancer that can hamper interval between
screening rounds, as seen in this case with no parenchymal or mediastinal abnormalities at year 2 (A and B), but evidence at
year 3 of untreatable neoplasm in an asymptomatic subject with a left parahilar solid mass (C) and subcarinal lymph node
enlargement with central necrosis (D). This case was conﬁrmed as extensive-stage SCLC by mediastinoscopy.
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percentage of NSCLC cases being diagnosed at an early
stage is increasing. In particular, because of its
extremely aggressive behavior, SCLC frequently occurs
as interval cancer despite annual LDCT screening. The
NELSON group observed an incidence of SCLC of
approximately 26 cases in 100,000 person-years, with
SCLC accounting for 7% of all tumors and representing
20% of all interval cancers. In particular, SCLC was
detected during screening in only 53% of cases.7 These
results are similar to those from our study, which re-
ported an incidence of SCLC of 22 cases in 100,000
person-years, with SCLC accounting for 6% of all lung
tumors and 8.6% of all interval cancers and being
detected by screening in 75% of cases. The NLST group
reported an incidence of SCLC of 83 cases in 100,000person-years and a frequency of 13% among all lung
tumors, with SCLC representing 34% of all interval
cancer cases and having a rate of detection during
screening of 66%.15 The higher incidence of SCLC in the
NLST than in our results and those of the NELSON
group likely reﬂects the higher median tobacco con-
sumption in the NLST (approximately 56 pack-years)16,17
than in European trials (39 and 38 pack-years, respec-
tively [Table 2]) and perhaps a slightly higher median age
(61 years versus 57 and 58 years, respectively).17 Of
note, the association between cigarette smoking and
SCLC was also observed within our cohort, in which
median number of pack-years in the SCLC group was
more than twice that in the overall population (82 and 39
pack-years) and also much higher than in the NSCLC
group (46 pack-years).
Figure 2. A false-positive ﬁnding requiring further investigation and non-screen-detected extensive-stage single cell lung
cancer in a participant undergoing biennial low-dose computed tomography (LDCT) scan. The speciﬁcity of LDCT for solid
noncalciﬁed nodules detected at baseline is low, which can necessitate further investigation (e.g., additional LDCT control
and positron emission tomography (PET)-CT characterization (A–F); this limitation is reﬂected in overdiagnosis of slow-
growing neoplasms or benign ﬁndings. On the other hand, screening with LDCT does not provide clinical improvement of
aggressive thoracic tumor (G–I). A noncalciﬁed solid pulmonary nodule of the left upper lobe was detected at T0 (A) and
remained stable over three biennial LDCT controls (B, C, and D), as well as on a CT scan with contrast agent that
was performed almost 2 years after the previous LDCT control (E). Thereafter, the nodule was conﬁrmed as benign by 18F-
ﬂuorodeoxyglucose–PET-CT (F). The subject underwent CT with a contrast agent for work-up of a cough with persistent
hemoptysis. The CT scan showed a left hilar mass with irregular reticulation of the adjacent lung parenchyma, suggesting
lymphangitis carcinomatosa (G) and diffuse mediastinal lymphadenomegaly with compression of the airways (H), which
showed high uptake of 18F-ﬂuorodeoxyglucose during PET-CT (I).
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outcome of SCLC in the setting of a lung cancer screening
trial. Median survival time in our study was slightly
longer than those reported in the clinical literature.14 We
think that this limited improvement should be attributed
to the anticipation of diagnosis rather than to actual
improvement of outcome. In this study, we report aFigure 3. Overall survival curve shows no survivors at 3 years
after diagnosis of SCLC.higher rate of ES-SCLC in the control group than in the
LDCT arm; however, the large number of LS-SCLC cases
in LDCT arms did not warrant signiﬁcant clinical
improvement. From our experience, the lack of real
advantage from early diagnosis was related to the poor
efﬁcacy of current treatment options for progression of
the disease.25,26 Surgery is usually not an option in such
subjects because systemic spread and paraneoplastic
syndrome typically impede the therapeutic potential of
resection. In particular, we reported an anecdotal case of
stage Ia SCLC in which radical surgery did not prevent
mediastinal relapse, systemic spread of the disease, and
cancer-related death within 3 years from diagnosis.
Dedicated research on novel medical therapy is being
fostered in an attempt to provide systemic treatment of
SCLC.27 Recently, the comprehensive genomic proﬁle of
110 patients with SCLC was investigated; the investiga-
tion found evidence of biallelic inactivation of the tumor
protein p53 gene (TP53) and the retinoblastoma 1 gene
(RB1) in more than 90% of the cases and inactivating
mutations in NOTCH family genes in 25% of them.28
Overall, the study identiﬁed several novel candidate
genes, some of which appear to be possible targets for
more efﬁcacious therapy for SCLC.28
Table 2. Incidence of SCLC and Proportion of SCLC with Respect to All Lung Cancers, Median Tobacco Consumption, and
Patient Agea
Lung Cancer
Screening Trial
SCLC
(n in 100,000 Person-Years)
SCLC as Percentage of
Lung Cancer Cases
(%)
Cumulative Tobacco
Consumption
(Median Pack-Years)
Age
(y)
NY-ELCAP18 69 10 40 66
DANTE19 97 8 47 64
DLST20,21 51 11 NA NA
NLST16,17 83 13 56 61
ITALUNG22 56 9 42 61
COSMOS23 81 10 NA 58
NELSON7 26 7 38 58
LUSI24 65 13 NA NA
Current study 22 6 39 57
aData are reported for major lung cancer screening trials worldwide, along with median tobacco consumption and age.
SCLC, small cell lung cancer; NY-ELAP, New York–Early Lung Cancer Action Project; DANTE, Dante Trial. A Randomized Study on Lung Cancer
Screening with Low-Dose Spiral Computed Tomography; DLST, Danish Lung Screening Trial; NA, not applicable; NLST, National Lung
Screening Trial; ITALUNG, Italian Lung Trial; COSMOS, Continuous Observation of Smoking Subjects; NELSON, Dutch-Belgian Lung Cancer
Screening Trial; LUS1, Lung Screening and Intervention trial.
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screening by LDCT that lies at the edge opposite over-
diagnosis, which was reported by Patz in more than 18%
of NSCLC.29 In particular, our results show that lung
cancer screening by LDCT is unable to improve the
outcome of SCLC. The only two subjects amenable to
surgical resection for curative purposes died within 2
years. This ﬁnding conﬁrms in practice the theory of
Baldwin et al., who postulated the insufﬁciency of annual
LDCT-screening for detection of fast-growing tumors
such as SCLC because they hamper a sustainable LDCT
screening protocol.30 Therefore, primary prevention
appears to be the only currently existing option for
reduction of mortality due to SCLC. Smoking cessation
programs should be regarded as a mandatory strategy
within screening and should be extensively implemented
in countries in which screening will be applied to general
population, such as the United States.31 On the basis of
our results, we suggest that a smoking cessation pro-
gram could be the optimal strategy to reduce mortality
due to SCLC, which is closely related to active smoking2
and shows a progressive decrease in risk by the time of
quitting smoking.32 Therefore, a smoking intervention
forearm of LDCT screening along with the use of active
drugs such as varenicline should be considered.33
This study has one main limitation: the small number
of SCLC cases, which limited the possibility of compari-
son between SCLC in the screening and control groups
and between screen-detected and non-screen-detected
SCLC. This limitation also prevented comparison of SCLC
with NSCLC. Another limitation is the presence of
recently diagnosed SCLC cases, for which long-term
evolution could not be described. However, they are
unlikely to improve the outcome of SCLC in the MILDtrial because of their advanced stage (all patients in
stage IV).
Conclusions
In conclusion, the subjects in whom SCLC developed
were a subgroup of smokers with extremely high cu-
mulative tobacco consumption. Accordingly, the fre-
quency of SCLC in our population was lower than in a
population with higher cumulative tobacco consumption.
Screening did not provide improvement of the thera-
peutic outcome of SCLC compared with that in clinical
reports. In our study, median overall time of survival of
LS-SCLC was slightly longer than that of ES-SCLC, which
is apparently related to anticipation of diagnosis. Surgery
was ineffective even in stage Ia SCLC, and no patients
were alive at 3 years.Acknowledgments
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